ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2012
Variation of second cancer risk by family history of retinoblastoma among long-term survivors.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 118 citations in OpenAlex.
- Incidence of second primary cancers in patients with retinoblastoma: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Risk of subsequent primary melanoma in 68 002 five-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup cohort study.Journal of the National Cancer Institute · 2026Article
- Subsequent Primary Hematologic Malignancies in a 21-Year-Old Retinoblastoma Survivor: Case Report Study.Cancer reports (Hoboken, N.J.) · 2025Article
- Metabolic Reprogramming in Retinoblastoma Patients: Treatment Naïve Active Retinoblastoma Versus Regressed Tumors Post-Treatment.Investigative ophthalmology & visual science · 2025Article
- Article
- Analysis of cytogenetic germline changes in Polish patients with retinoblastoma.Molecular vision · 2025Article
- Prognostic importance of direct assignment of parent of origin via long-read genome and epigenome sequencing in retinoblastoma.JCI insight · 2024Article
- Epidemiology, Diagnosis and Genetics of Retinoblastoma: ICMR Consensus Guidelines.Indian journal of pediatrics · 2024Review
- Non-RB1 germline cancer predisposing variants found in retinoblastoma patients.Genetics in medicine open · 2024Article
- [Imaging of retinoblastoma : Current state-of-the-art and future prospects].Radiologie (Heidelberg, Germany) · 2022Review
- Increased Risk of Skin Cancer in 1,851 Long-Term Retinoblastoma Survivors.The Journal of investigative dermatology · 2021Article
- Introduction of a Variant Classification System for Analysis of Genotype-Phenotype Relationships in Heritable Retinoblastoma.Cancers · 2021Article
- Review
- RB Regulates DNA Double Strand Break Repair Pathway Choice by Mediating CtIP Dependent End Resection.International journal of molecular sciences · 2020Article
- Next generation sequencing of RB1gene for the molecular diagnosis of ethnic minority with retinoblastoma in Yunnan.BMC medical genetics · 2020Article
- Recommendations for Long-Term Follow-up of Adults with Heritable Retinoblastoma.Ophthalmology · 2020Review
- Incidence and Mortality of Second Primary Cancers in Danish Patients With Retinoblastoma, 1943-2013.JAMA network open · 2020Article
- Cell-free DNA profiling in retinoblastoma patients with advanced intraocular disease: An MSKCC experience.Cancer medicine · 2020Article
- Evolution of Care of Orbital Tumors with Radiation Therapy.Journal of neurological surgery. Part B, Skull base · 2020Article
- Next-Generation Sequencing of Retinoblastoma Identifies Pathogenic Alterations beyond RB1 Inactivation That Correlate with Aggressive Histopathologic Features.Ophthalmology · 2020Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo evaluate the risk of second cancer (SC) in long-term survivors of retinoblastoma (Rb) according to classification of germline mutation, based on family history of Rb and laterality. PATIENTS AND
methodsWe assembled a cohort of 1,852 1-year survivors of Rb (bilateral, n = 1,036; unilateral, n = 816). SCs were ascertained by medical records and self-reports and confirmed by pathology reports. Classification of RB1 germline mutation, inherited or de novo, was inferred by laterality of Rb and positive family history of Rb. Standardized incidence ratios and cumulative incidence for all SCs combined and for soft tissue sarcomas, bone cancers, and melanoma were calculated. The influence of host- and therapy-related risk factors for SC was assessed by Poisson regression for bilateral survivors.
resultsWe observed a relative risk (RR) of 1.37 (95% CI, 1.00 to 1.86) for SCs in bilateral survivors associated with a family history of Rb, adjusted for treatment, age, and length of follow-up. The risk for melanoma was significantly elevated for survivors with a family history of Rb (RR, 3.08; 95% CI, 1.23 to 7.16), but risks for bone or soft tissue sarcomas were not elevated. The cumulative incidence of SCs 50 years after diagnosis of bilateral Rb, with adjustment for competing risk of death, was significantly higher for survivors with a family history (47%; 95% CI, 35% to 59%) than survivors without a family history (38%; 95% CI, 32% to 44%; P = .004).
conclusionRb survivors with bilateral disease and an inherited germline mutation are at slightly higher risk of an SC compared with those with a de novo germline mutation, in particular melanoma, perhaps because of shared genetic alterations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.